Press Releases Year All News20192018201720162015 Forty Seven Inc. Reports Second Quarter 2019 Financial Results and Recent Business Highlights August 13, 2019 Forty Seven Inc. to Report Second Quarter 2019 Financial Results on Tuesday, August 13, 2019 August 6, 2019 Forty Seven, Inc. Announces $6 Million in Funding from the Leukemia & Lymphoma Society TAP to Accelerate the Development of 5F9 in Myelodysplastic Syndrome August 6, 2019 Forty Seven Inc. to Present at Canaccord Genuity 39th Annual Growth Conference July 31, 2019 Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares July 22, 2019 Forty Seven, Inc. Prices Underwritten Public Offering of 9,375,000 Shares of Common Stock July 17, 2019 Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock July 16, 2019 Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Select Countries in Southeast Asia July 11, 2019 Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma June 15, 2019 Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia June 3, 2019 Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 22
